Glaukos
Open
$126.96
Prev. Close
$126.96
High
$127.21
Low
$126.48
Market Snapshot
$7.36B
-38.9
-2.80
$383.48M
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in Aliso Viejo, California and currently employs 1,094 full-time employees. The company went IPO on 2015-06-25. The firm is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in Aliso Viejo, California and currently employs 1,094 full-time employees. The company went IPO on 2015-06-25. The firm is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
Recently from Cashu
Glaukos Gains Investor Confidence with Permanent HCPCS J-Code for Epioxa Treatment
Glaukos Corporation (GKOS) has experienced a resurgence in investor confidence following the announcement that the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a permanent Health…
No content provided for summarization regarding Glaukos. Please share details.
I’m sorry, but it appears that you did not provide the content you would like me to summarize. Please share the relevant information regarding Glaukos or the specific developments, and I will create t…
Please provide the text you would like me to summarize, and I will be happy to help!
Please provide the text you would like me to summarize, and I will be happy to help!
Glaukos Flags "Mixed" Quarter, Provides No Revenue or Financial Metrics
Glaukos flags mixed quarter but offers no numbers Glaukos Corp, the ophthalmic medical‑device maker, announces mixed results for its fourth quarter on Tuesday but supplies no accompanying quantitative…